Article
Impact of KRASG12D subtype and concurrent pathogenic mutations on advanced non-small cell lung cancer outcomes.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico - 1 Apr 2024
Caballé-Perez Enrique, Hernández-Pedro Norma, Ramos-Ramírez Maritza, Barrios-Bernal Pedro, Romero-Núñez Eunice, Lucio-Lozada José, Ávila-Ríos Santiago, Reyes-Terán Gustavo, Cardona Andrés F, Arrieta Oscar
Abstract excerpt
PURPOSE: Mutations in the Kirsten rat sarcoma viral (KRAS) oncogene constitute a significant driver of lung adenocarcinoma, present in 10-40% of patients, which exhibit heterogeneous clinical outcomes, mainly driven by concurrent genetic alterations. However, characterization of KRAS mutational subtypes and their impact on clinical outcomes in Latin America is limited. METHODS: A cohort study was conducted at the...
Topics
- Female
- Humans
- Carcinoma, Non-Small-Cell Lung
- Cohort Studies
- Lung Neoplasms
- Mutation
- Proto-Oncogene Proteins p21(ras)
